Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 20,927 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Recruiting Not applicable Interventional

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

NCT06437028
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Dual-layer perinatal tissue allograft, Three-layer fenestrated perinatal tissue allograft, Standard of care
Other
Lead sponsor
Samaritan Biologics
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Monroe, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional Results available

CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management

NCT03676465
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CloudConnect Report, Will not receive a CloudConnect Report
Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Nov 4, 2026, 5:13 PM EST
Completed Phase 3 Interventional Results available

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00088530
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
9
States / cities
Fountain Valley, California • Los Angeles, California • Lakeland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 4, 2026, 5:13 PM EST
Active, not recruiting Phase 2 Interventional

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

NCT04367311
View directory record Official record
Conditions
Lung Cancer, NSCLC
Interventions
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Drug
Lead sponsor
Nasser Hanna
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 4, 2026, 5:13 PM EST
Withdrawn Not applicable Interventional

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

NCT01769911
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I AIDS-related Lymphoma, Stage II AIDS-related Lymphoma, Stage III AIDS-related Lymphoma, Stage IV AIDS-related Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
carmustine, cytarabine, melphalan, etoposide, O6-benzylguanine, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Nov 4, 2026, 5:13 PM EST
Terminated Phase 1 Interventional Results available

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT00860171
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis
Procedure · Radiation · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional

Developing Inclusive Support and Intervention for Spanish-speaking Latiné Prostate Cancer Survivors

NCT06435871
View directory record Official record
Conditions
Prostate Cancer
Interventions
Expanded Prostate Cancer Index Composite and Decision Regret Scale
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 4, 2026, 5:13 PM EST
Completed No phase listed Observational

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

NCT06150534
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Nov 4, 2026, 5:13 PM EST
Completed No phase listed Observational

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

NCT04014764
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm
Interventions
This is a non-interventional study
Other
Lead sponsor
Notable Labs
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Bakersfield, California • San Luis Obispo, California • Grand Junction, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Nov 4, 2026, 5:13 PM EST
Completed No phase listed Observational Results available

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

NCT04053699
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Von Willebrand Factor-Containing Product
Drug
Lead sponsor
Octapharma
Industry
Eligibility
66 Months and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Nov 4, 2026, 5:13 PM EST
Terminated Phase 1 Interventional

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

NCT00745732
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ZD6474 (ZACTIMA), Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Nov 4, 2026, 5:13 PM EST
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional Results available

BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease

NCT02655887
View directory record Official record
Conditions
May-Thurner Syndrome, Peripheral Vascular Disease, Venous Disease, Iliofemoral Occlusive Disease
Interventions
VENOVO™ Venous Stent
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Darien, Connecticut • New Haven, Connecticut • Davenport, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional

TDCS for Cocaine Addiction Craving

NCT03833583
View directory record Official record
Conditions
Cocaine Use Disorder, Cocaine Dependence
Interventions
Soterix Medical mini-CT tDCS stimulator
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men

NCT06362941
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Women's Hair Growth Supplemnt, Nutrafol Women's Balance Hair Growth Supplement, Nutrafol Women's Vegan Hair Growth Supplement, Nutrafol Women's Postpartum Hair Growth Supplement, Nutrafol Men's Hair Growth Supplement
Dietary Supplement
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Nov 4, 2026, 5:13 PM EST
Completed Early Phase 1 Interventional Results available

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

NCT00734994
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Interventions
Hyperthermia System, Mitomycin C
Device · Drug
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting

NCT03034694
View directory record Official record
Conditions
Cellulitis
Interventions
teledermatology consult, Routine Care
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Nov 4, 2026, 5:13 PM EST
Completed Phase 2 Interventional Results available

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

NCT03322566
View directory record Official record
Conditions
Lung Cancer
Interventions
Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis

NCT06441266
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview
Drug · Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 4, 2026, 5:13 PM EST
Completed Not applicable Interventional

A Study Examining Changes in Pain After Manual Therapy in People With Achilles Tendon Pain

NCT06134856
View directory record Official record
Conditions
Achilles Tendinopathy, Ankle Strain, Achilles Tendon Pain, Achilles Tendonitis
Interventions
Ankle mobilization, Sham treatment
Procedure
Lead sponsor
Philadelphia College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Suwanee, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Nov 4, 2026, 5:13 PM EST
Active, not recruiting Phase 4 Interventional

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

NCT06765356
View directory record Official record
Conditions
Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Long-standing Persistent Atrial Fibrillation
Interventions
Farapulse Catheter System, Low-dose Colchicine
Device · Drug
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Jonesboro, Arkansas • Ventura, California • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 4, 2026, 5:13 PM EST
Terminated Phase 2 Interventional

Study of XL999 in Patients With Non-small Cell Lung Cancer

NCT00277329
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
XL999
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Port Saint Lucie, Florida • Joliet, Illinois • Nyack, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Nov 4, 2026, 5:13 PM EST
Active, not recruiting Not applicable Interventional

Cryoneurolysis for Painful Diabetic Neuropathy of the Foot

NCT06646731
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
cryoneurolysis, sham cryoneurolysis
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 4, 2026, 5:13 PM EST
Not listed Not applicable Interventional

Dissemination of the Cardiovascular Risk Service

NCT03660631
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
CVRS Intervention
Behavioral
Lead sponsor
Korey Kennelty
Other
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
14
States / cities
Pocatello, Idaho • Chicago, Illinois • Mahomet, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Nov 4, 2026, 5:13 PM EST